A427 the analysis. The model's effectiveness outcome is defined as patients who are successfully treated and are alive. Cost-effectiveness is measured as total costs per patient with respect to effectiveness for each medication arm. In addition, sensitivity analyses were performed to identify cost-effectiveness for different clinical and economic assumptions. RESULTS: The analysis shows that 60% of MICA patients were successfully treated and survived at the end of study compared to 58% of CASPO patients. Furthermore, the costs of a MICA treatment (a37,212) are below the costs of a CASPO treatment (a37,720). Therefore, the cost-effectiveness ratio is lower for MICA (a62,377) than for CASPO (a65,565). This result also holds for all but one of the sensitivity analyses. However, probabilistic sensitivity and subgroup analyses show that differences cannot be considered statistically significant due to large variance. For European patients only, who can be assumed to be a more homogenous group and a better approximation of German patients, cost-effectiveness ratio for MICA is 59,406 a compared to a68,217 for CASPO, the difference being statistically significant. CONCLUSIONS: This study analyzes the cost-effectiveness of MICA as compared to CASPO for the treatment of systemic candida infections in Germany. Both lower costs and higher effectiveness of MICA render MICA as more cost-effective than CASPO. OBJECTIVES: To establish a cost-effective intravenous antibiotic therapy in the treatment of Infective Endocarditis and Bacteremia. METHODS: A cost-effectiveness study was performed considering the expenses and use of resources of Mexican Public Health Institutions. The study was based on a decision tree with Bayesian approach defining three different health states: clinical success (within short or long hospital stay frame), therapeutic failure, and death. The alternatives compared were: a) i.v. Vancomycin (VAN) as a first-line antibiotic therapy followed by a second-line antibiotic therapy in therapeutic failure, or b) i.v. Daptomycin (DAP) as a first-line or second-line antibiotic therapy. The most recent published data concerning efficacies, length of hospital stay and adverse events were included in the study. Results were evaluated with incremental analysis and one-way sensitivity analysis of most uncertain variables.
PIN52 COST ESTIMATES IN THE ECONOMIC EVALUATIONS OF VACCINATION PROGRAMMES: THE CASES OF ROTAVIRUS AND VARICELLA IN BRAZIL
Valentim J, Sartori A, Amaku M, Soarez P, Azevedo R, Novaes H University of São Paulo, São Paulo, SP, Brazil OBJECTIVES: To estimate the impact of the use of more detailed direct medical costs for the economic evaluations (EEs) of universal vaccinations against rotavirus and varicella in Brazil on the incremental cost-effectiveness ratios (ICERs). METHODS: Previous published EEs were used as basis and new direct medical costs estimates for rotavirus and varicella were developed, with the inclusion of specific costs of the private health care system (HCS) for the two diseases, inclusion of public participation for dispensing drugs in the case of rotavirus and inclusion of drugs costs in the public HCS in the case of varicella. Cost estimate methods consisted of gross-costing and microcosting. Data were obtained from national regulatory agency database (ANS), household survey (PNAD), private (CBHPM, TUNEP) and public (Ministry of Health) reference lists. Direct medical costs were then applied to the previous models, preserving non-medical direct and indirect costs, all costs in 2004 Reals. ICERs were recalculated and compared to the original calculations, from the HCS and societal perspective. Univariate sensitivity analysis was performed to each cost item and discount rate to analyse individual impact on ICER. RESULTS: From the societal perspective, there was an estimated disease total cost increase of 16% for rotavirus and 11% for varicella, as well as increase of savings with the vaccination of 18% and 16%, respectively. ICERs were reduced by 20% for rotavirus (to a292/LYS) and 4% for varicella (to a4098/LYS), still below the threshold (3xGDP per capita). Sensitivity analysis indicated that EEs of vaccination against rotavirus and varicella were more sensitive to the vaccination program cost estimates, especially the vaccine price. CONCLUSIONS: Although the more detailed cost estimates reduced the ICERs, the level of cost-effectiveness of the two vaccination programs remained the same. Sensitivity analysis pointed out the relevance of the vaccine cost comparatively to the direct medical costs.
PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE 1 (G1) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE
Jensen DM 1 , Marcellin P 2 , Urspruch A 3 , Papadakis K 4 , Tonev D 4 1 University of Chicago Medical Center, Chicago, IL, USA, 2 Hôpital Beaujon, Clichy, France, 3 F. Hoffmann La Roche Ltd., Basel, Switzerland, 4 Roche Products Ltd., Welwyn Garden City, UK OBJECTIVES: Standard treatment for hepatitis C is peginterferon (PEG-IFN) RBV with the aim of achieving a sustained-virological-response (SVR), which is widely considered to be a cure. Around 50% of patients infected with G1 do not achieve an SVR but re-treatment with PEG-IFN RBV is successful in some, especially in those who achieve a complete-early-virological-response (HCV-RNA undetectable by week 12 [cEVR] ). The objective of this analysis was to determine the cost-effectiveness of re-treating previous G1-non-responders to PEG-IFN RBV. METHODS: A published Markov-model compared three strategies: PEG-IFN 2a RBV, for 72 weeks (A), 48 weeks (B) or no treatment (C). Efficacy data for (A) and (B) were taken from the REPEAT study, where a difficult-to-treat population of G1-patients with previous non-response to PEG-IFN/RBV was investigated. Rates of cEVR were 15% for (A) and 9% for (B); SVR rates: 13% for (A) and 7% for (B); rates for (C) assumed to be zero. Patients not achieving a cEVR were assumed to discontinue treatment. A UK health care payor perspective was adopted. Drug and other costs were taken from published sources. A lifetime-horizon was chosen. Incremental-cost-effectivenessratios were expressed as cost per quality-adjusted-life-year (QALY). Costs and QALYs were discounted at 3.5% p.a. Sensitivity-analyses were performed. RESULTS: The analysis showed that an additional SVR prevented future costs and increased quality-adjusted-life-expectancy. Although (A) caused the highest overall drug costs, total costs were only £606 higher compared to (B) and £1949 compared to (C), reflecting the higher SVR rates and the substantial medical costs for patients without an SVR. The ICER of (A) vs. (B) was estimated at £2,012/QALY and £2,988/QALY for (A) vs. (C). CONCLUSIONS: Re-treatment with PEG-IFN 2a RBV for 72 weeks is a highly cost-effective treatment option for patients not responding to previous treatment with PEG-IFN RBV, regardless of comparator, due to reduction of the high medical costs associated with progressive liver disease and the associated QALY gains.
PIN54 THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCV13) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK
Patel R 1 , Stoykova B 2 , Lloyd AC 1 , Willingham J 2 , Hollingsworth R 2 1 IMS Health, London, UK, 2 Wyeth, Maidenhead, Berkshire, UK OBJECTIVES: The 7-valent pneumococcal conjugate vaccine (PCV7) and 23-valent pneumococcal polysaccharide vaccine (PPV23) are currently recommended for childhood and adult vaccination respectively in the UK. A 13-valent pneumococcal conjugate vaccine (PCV13) is currently being reviewed by regulatory authorities for use in infants and young children, and a clinical development plan for adults is ongoing. This study assessed cost-effectiveness of PCV13 compared to the current vaccination strategy and to PCV7 given to children alone. METHODS: A steady state, static cohort model was constructed comparing PCV13 vaccination of the birth cohort and of 65-year old adults with the current strategy and with PCV7 in children alone. The model con sidered the incidence and subsequent costs of four infections: pneumococcal meningitis; pneumococcal bacteraemia; all cause pneumonia and acute otitis media (AOM). Vaccination was assumed to have effects on vaccinated individuals and to impact unvaccinated individuals as a result of herd immunity. The number of cases and subsequent costs that would occur were estimated in the different scenarios. Sensitivity analysis considered incidence, mortality rates, vaccine efficacy, serotype cover, costs, discount rate, uptake and herd immunity. RESULTS: The model estimated that, compared to the current strategy (and compared to PCV7 alone), PCV13 would reduce the annual incidence of bacteraemia and meningitis by 1176 (1303) cases, prevent 35 (40) deaths, increase life years by 619 (666), increase QALYs by 694 (731) and reduce medical costs by £2.9m (£11.1m). Results are sensitive to vaccine effects against pneumonia and the disease incidence in non-vaccinated individuals. CONCLUSIONS: Paediatric and adult PCV13 vaccination in the UK was estimated to reduce the burden of pneumococcal disease and save costs compared with either the current vaccination strategy or a paediatric PCV7 only strategy. Final cost-effectiveness will depend on the emergence of herd immunity benefits in the UK, impact on pneumonia, vaccine schedule and price. To determine the cost-effectiveness of the protocol of the international 'Surviving Sepsis Campaign' (SSC) for the treatment of severe sepsis in Spain after the implementation of a multicentre educational program compared with the conventional
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COST-EFFECTIVENESS OF THE SURVIVING SEPSIS CAMPAIGN PROTOCOL FOR SEVERE SEPSIS IN SPAIN
